WitrynaThe latest analysis “provides further assurance” that giving trastuzumab after standard chemotherapy is effective for treatment of early HER2-positive breast cancer and that such treatment “continues to show a generally favorable safety profile with a low rate of congestive heart failure,” Dr. Joensuu wrote. Questions still remain about ... WitrynaHerceptin alone is approved for the treatment of HER2-positive breast cancer in patients who have received one or more chemotherapy courses for metastatic disease. As part of a treatment course including the chemotherapy drugs doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. This treatment course is known as “AC TH”.
Paclitaxel and carboplatin Macmillan Cancer Support
Witryna27 mar 2024 · Purpose Uterine serous carcinoma is a rare, aggressive variant of endometrial cancer. Trastuzumab is a humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2)/neu, a receptor overexpressed in 30% of uterine serous carcinoma. This multicenter, randomized phase II trial compared … Witryna12 lip 2024 · Background – Endometrial cancer and this trial. Uterine-serous-carcinoma, USC, is an aggressive variant of endometrial cancer.This phase II trial evaluated Carboplatin+Taxol versus Herceptin +Carboplatin+Taxol in patients with advanced or recurrent uterine serous carcinomas that express HER2, HER2+. … send refresh token in header
Endometrial Serous Carcinoma stage 3C - Page 2
WitrynaCarboplatin + paclitaxel (also known as Carbo/Taxol) may be given with the goal of cure if the disease is not metastatic (spread to other areas of the body). If the disease is metastatic, it may be given to decrease the symptoms of uterine cancer and prolong life. Schedule. Carboplatin intravenous (I.V.) infusion over 30 to 60 minutes on Day 1 WitrynaPaclitaxel and carboplatin is used to treat lung, ovarian, womb and cervical cancer. It may sometimes be used to treat other cancers. It is best to read this information with our general information about chemotherapy and the type of cancer you have.. Your doctor will talk to you about this treatment and its possible side effects before you agree to … WitrynaThe incidence and mortality rates from endometrial cancer continue to increase worldwide, while rates in most other cancers have either plateaued or declined considerably. Uterine serous carcinoma represents a fraction of all endometrial malignancies each year, yet this histology is responsible for nearly 40% of all … send recurring email microsoft